Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, Granada, 18100, Spain.
Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, Granada, 18071, Spain.
Int J Nanomedicine. 2022 Oct 31;17:5065-5080. doi: 10.2147/IJN.S368814. eCollection 2022.
The failure of chemotherapeutic treatment in colorectal cancer (CRC), the second most mortal cancer worldwide, is associated with several drug limitations, such as non-selective distribution, short half-life, and development of multiple resistances. One of the most promising strategies in CRC therapy is the development of delivery systems based on nanomaterials that can transport antitumor agents to the tumor site more efficiently, increasing accumulation within the tumor and thus the antitumor effect. In addition to taking advantage of the increased permeability and retention effect (EPR) of solid tumors, these nanoformulations can be conjugated with monoclonal antibodies that recognize molecular markers that are specifically over-expressed on CRC cells. Active targeting of nanoformulations reduces the adverse effects associated with the cytotoxic activity of drugs in healthy tissues, which will be of interest for improving the quality of life of cancer patients in the future. This review focuses on in vitro and in vivo studies of drug delivery nanoformulations functionalized with monoclonal antibodies for targeted therapy of CRC.
化疗治疗结直肠癌（CRC）的失败，CRC 是全球第二大致命癌症，与几种药物限制有关，例如非选择性分布、半衰期短和多种耐药性的发展。在 CRC 治疗中，最有前途的策略之一是开发基于纳米材料的输送系统，这些系统可以更有效地将抗肿瘤药物输送到肿瘤部位，增加肿瘤内的积累，从而提高抗肿瘤效果。除了利用实体瘤的增强通透性和保留效应（EPR）外，这些纳米制剂还可以与单克隆抗体偶联，这些抗体可以识别在 CRC 细胞上特异性过表达的分子标记物。纳米制剂的主动靶向减少了与药物在健康组织中的细胞毒性活性相关的不良反应，这将有助于提高癌症患者的生活质量。本综述重点介绍了用单克隆抗体功能化的药物输送纳米制剂的体外和体内研究，用于 CRC 的靶向治疗。
